- Molecular NameCidofovir
- SynonymCDV; Cidofovir Anhydrous
- Weight279.189
- Drugbank_IDDB00369
- ACS_NO113852-37-2
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-3.88
- pkaN/A
- LogD (pH=7, predicted)-8.26
- Solubility (experiment)170 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.55
- LogSw (predicted, AB/LogsW2.0)100.74
- Sw (mg/ml) (predicted, ACD/Labs)38.93
- No.of HBond Donors5
- No.of HBond Acceptors9
- No.of Rotatable Bonds6
- TPSA155.49
- StatusFDA approved
- Administrationintravenous
- PharmacologyCidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection.
- Absorption_value3.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability5.0
- Protein binding6.0
- Volume of distribution (VD)0.36 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExcreted as unchanged drug.
- Half life2.3 h (cidofovir); 17~65 h (active metabolite, cidofovir diphosphate)
- Excretiont is excreted largely unchanged in urine by glomerular filtration and tubular secretion. About 80 to 100% of a dose is recovered unchanged in urine over 24 h. No active metabolites are detected in serum. It is given concurrently with prehydration and oral probenecid to block the tubular secretion and thus reduce high concentrations in the kidney, since cidofovir is nephrotoxic.
- Urinary Excretion70.1
- Clerance2.1 ml/min/kg
- ToxicityKidney damage, fall in the number of white blood cells, decreased platelets
- LD50 (rat)N/A
- LD50 (mouse)N/A